Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cardiol
Autors principals: Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Format: Artigo
Idioma:Inglês
Publicat: Wiley Periodicals, Inc. 2017
Matèries:
Trial Designs
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396348/
https://ncbi.nlm.nih.gov/pubmed/28294373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22692
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars